公开(公告)号：US09060974B1

公开(公告)日：2015-06-23

申请号：US13134326

申请日：2011-06-06

Applicant: Weidong Zhang ,  Lixian Jiang ,  Calvin Cao

Inventor： Weidong Zhang ,  Lixian Jiang ,  Calvin Cao

IPC: A01N63/00 ,  A61K39/155

CPC classification number: A61K39/155 ,  A61K35/76 ,  A61K35/768 ,  C12N7/00 ,  C12N2760/18032 ,  C12N2760/18511 ,  C12N2760/18532 ,  C12N2760/18543

Abstract: The present invention is within the field of oncolytic virotherapy. Oncolytic virotherapy is a strategy using viruses, naturally occurring or genetically modified, to selectively target and destroy tumor cells while leaving surrounding non-malignant cells unharmed Here, an engineered respiratory syncytial virus (RSV), with the NS1 gene deleted (NS1 gene-deficient RSV, ΔNS1 RSV), kills prostate cancer cells, but does not affect normal human cells.

Abstract translation: 本发明属于溶瘤病毒疗法领域。 溶瘤病毒疗法是使用天然存在或遗传修饰的病毒选择性靶向和破坏肿瘤细胞同时使周围的非恶性细胞不受伤害的策略的策略。这里，NS1基因缺失的工程化呼吸道合胞病毒（RSV）（NS1基因缺陷型） RSV，＆Dgr; NS1 RSV），杀死前列腺癌细胞，但不影响正常人细胞。

公开(公告)号：US08088748B2

公开(公告)日：2012-01-03

申请号：US12259155

申请日：2008-10-27

Applicant: Stephania Cormier

Inventor： Stephania Cormier

IPC: C12N15/11 ,  C07H21/07 ,  A61K39/155

CPC classification number: C12N15/1138 ,  C12N2310/11 ,  C12N2760/18511

Abstract: A method is provided for immunizing against pulmonary inflammation and airway hyperresponsiveness associated with infantile RSV infection. This method includes administering an antisense oligonucletide to a subject in need thereof.

Abstract translation: 提供了用于免疫与婴儿RSV感染相关的肺部炎症和气道高反应性的方法。 该方法包括向有需要的受试者施用反义寡核苷酸。

公开(公告)号：US20110189171A1

公开(公告)日：2011-08-04

申请号：US12974585

申请日：2010-12-21

Applicant: Johan Lantto ,  Henriette Schjonning Nielsen

Inventor： Johan Lantto ,  Henriette Schjonning Nielsen

IPC: A61K39/42 ,  C07K16/10 ,  C07H21/00 ,  A61P31/14

CPC classification number: C07K16/1027 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  C12N2760/18511

Abstract: Disclosed are novel polyclonal antibodies, which target respiratory syncytial virus (RSV), as well as novel high affinity antibody molecules reactive with RSV. The polyclonal antibodies may comprise antibody molecules which are reactive with both RSV protein F and RSV protein G, and preferably the polyclonal antibodies target a variety of epitopes on these proteins. The antibody molecules of the invention have shown superior efficacy in vitro and/or in vivo. Also disclosed are methods of producing the antibodies of the invention as well as methods of their use in treatment or prevention of RSV infection.

Abstract translation: 公开了靶向呼吸道合胞病毒（RSV）的新型多克隆抗体，以及与RSV反应的新型高亲和力抗体分子。 多克隆抗体可以包含与RSV蛋白F和RSV蛋白G两者都具有反应性的抗体分子，优选多克隆抗体靶向这些蛋白质上的多种表位。 本发明的抗体分子在体外和/或体内显示出优异的功效。 还公开了产生本发明的抗体的方法以及它们在治疗或预防RSV感染中的用途。

公开(公告)号：US20180320146A1

公开(公告)日：2018-11-08

申请号：US16030259

申请日：2018-07-09

Applicant: THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY

Inventor： Antonius G.P. Oomens

IPC: C12N7/00 ,  C07K14/005 ,  C12Q1/06

CPC classification number: C12N7/00 ,  A61K2039/5254 ,  A61K2039/5258 ,  C07K14/005 ,  C12N2760/18511 ,  C12N2760/18522 ,  C12N2760/18523 ,  C12N2760/18534 ,  C12N2760/18562 ,  C12Q1/06 ,  G01N2333/115 ,  G01N2500/00

Abstract: Highly antigenic yet safe vaccines against diseases caused by Paramyxoviridae viruses such as respiratory syncytial virus (RSV) are provided. The vaccines comprise attenuated Paramyxoviridae viruses with high antigenicity but which display impaired cell-to-cell transmission as a result of genetic manipulation of the gene encoding the matrix (M) protein. In the viruses, the M protein is absent or mutated to a less active form. Screening or assay systems and methods for evaluating the infectivity of mutant M proteins anf for identifying suitable M candidates for live-attenuated vaccine virus and VLP production, are also provided.

公开(公告)号：US20180065932A1

公开(公告)日：2018-03-08

申请号：US15678901

申请日：2017-08-16

Applicant: Alios BioPharma, Inc.

Inventor： Guangyi Wang ,  Leonid Beigelman ,  Anh Truong ,  Carmela Napolitano ,  Daniele Andreotti ,  Haiying He ,  Karin Ann Stein

IPC: C07D213/40 ,  A61K45/06 ,  A61K31/437 ,  A61K31/4355 ,  A61K31/444 ,  A61K31/4709 ,  C07D401/04 ,  C07D409/04 ,  C07D495/14 ,  C07D413/04 ,  C07D417/04 ,  C07D239/34 ,  C07D471/04 ,  C07D213/65 ,  C07D401/12 ,  C07D491/048 ,  C07D233/64 ,  C07D409/14 ,  C07D417/06 ,  C07D413/12 ,  C07D413/06 ,  C07D401/06 ,  C07D405/12 ,  A61K31/4436 ,  C07D417/12 ,  C07D207/273 ,  A61K31/505 ,  A61K31/427 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/4365 ,  A61K31/4439 ,  A61K31/4178 ,  A61K31/4418 ,  C07D491/052

CPC classification number: C07D213/40 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4355 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4418 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/505 ,  A61K45/06 ,  A61K2300/00 ,  C07D207/273 ,  C07D213/65 ,  C07D233/64 ,  C07D239/34 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/06 ,  C07D413/12 ,  C07D417/04 ,  C07D417/06 ,  C07D417/12 ,  C07D471/04 ,  C07D491/048 ,  C07D491/052 ,  C07D495/14 ,  C12N2760/18511

Abstract: Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

公开(公告)号：US20160024476A1

公开(公告)日：2016-01-28

申请号：US14775484

申请日：2014-03-14

Applicant: UNIVERSITÉ DE GENÈVE

Inventor： Elodie Anne Françoise BELNOUE ,  Stéphanie Gabrielle DARBRE ABDELRAHMAN ,  Arun Thomas KAMATH ,  Paul LAMBERT ,  Claire-Anne SIEGRIST-JULLIARD ,  Daniel David PINSCHEWER

IPC: C12N7/00 ,  A61K39/02 ,  A61K35/76

CPC classification number: C12N7/00 ,  A61K35/76 ,  A61K39/02 ,  A61K39/04 ,  C12N2760/10021 ,  C12N2760/10031 ,  C12N2760/18511 ,  C12N2760/18534 ,  C12N2810/85

Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against mycobacterial infections. The invention also relates to pharmaceutical compositions and methods for the prevention and treatment of mycobacterial infections. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing and treating infections in Mycobacterium tuberculosis.

Abstract translation: 本文提供了适合作为针对分枝杆菌感染的疫苗的遗传修饰的纳豆病毒。 本发明还涉及用于预防和治疗分枝杆菌感染的药物组合物和方法。 具体地，本文提供的是药物组合物，疫苗，以及预防和治疗结核分枝杆菌感染的方法。

公开(公告)号：US20150110825A1

公开(公告)日：2015-04-23

申请号：US14495640

申请日：2014-09-24

Applicant: Massachusetts Institute of Technology

Inventor： Ram SASISEKHARAN ,  Aditya RAGURAM ,  Vidya SUBRAMANIAN

IPC: A61K39/155 ,  A61K47/48 ,  C07K14/00 ,  C12N7/00 ,  C07K14/205

CPC classification number: A61K39/155 ,  A61K39/02 ,  A61K39/12 ,  A61K47/6931 ,  C07K14/00 ,  C07K14/135 ,  C07K14/205 ,  C07K2319/00 ,  C07K2319/70 ,  C07K2319/735 ,  C12N7/00 ,  C12N2760/18022 ,  C12N2760/18034 ,  C12N2760/18511 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2760/18571

Abstract: The present invention provides nanoparticles and compositions of various constructs that combine meta-stable viral proteins (e.g., RSV F protein) and self-assembling molecules (e.g., ferritin, HSPs) such that the pre-fusion conformational state of these key viral proteins is preserved (and locked) along with the protein self-assembling into a polyhedral shape, thereby creating nanoparticles that are effective vaccine agents. The invention also provides nanoparticles comprising a viral fusion protein, or fragment or variant thereof, and a self-assembling molecule, and immunogenic and vaccine compositions including the same.

Abstract translation: 本发明提供了组合元稳定病毒蛋白（例如RSV F蛋白）和自组装分子（例如铁蛋白，HSP）的各种构建体的纳米颗粒和组合物，使得这些关键病毒蛋白的融合前构象状态是 保存（和锁定）以及蛋白质自组装成多面体形状，从而产生作为有效疫苗剂的纳米颗粒。 本发明还提供包含病毒融合蛋白或其片段或变体和自组装分子的纳米颗粒，以及包含其的免疫原性和疫苗组合物。

公开(公告)号：US20230167178A1

公开(公告)日：2023-06-01

申请号：US17812492

申请日：2022-07-14

Applicant: MacroGenics, Inc. ,  Duke University

Inventor： Scott Koenig ,  Leslie S. Johnson ,  Chia-Ying Kao Lam ,  Liqin Liu ,  Jeffrey Lee Nordstrom ,  Barton F. Haynes ,  Guido Ferrari

IPC: C07K16/28 ,  C12N5/0783 ,  C07K16/10 ,  C07K16/08

CPC classification number: C07K16/283 ,  C12N5/0638 ,  C07K16/1027 ,  C07K16/1063 ,  C07K16/2809 ,  C07K16/084 ,  C07K16/085 ,  C12N2510/00 ,  C12N2710/16211 ,  C12N2710/20011 ,  C12N2740/16111 ,  C12N2760/18511 ,  C07K2317/626 ,  C07K2317/31 ,  C07K2317/73 ,  A61K2039/505

Abstract: The present invention relates to bispecific molecules that are capable of localizing an immune effector cell that expresses an activating receptor to a virally infected cell, so as to thereby facilitate the killing of the virally infected cell. In a preferred embodiment, such localization is accomplished using bispecific molecules that are immunoreactive with an activating receptor of an immune effector cell and to an antigen expressed by a cell infected with a virus wherein the antigen is detectably present on the cell infected with the virus at a level that is greater than the level at which the antigen is detected on the virus by the bispecific molecules, and to the use of such bispecific molecules in the treatment of latent viral infections.

公开(公告)号：US20160017038A1

公开(公告)日：2016-01-21

申请号：US14775041

申请日：2014-03-13

Applicant: MACROGENICS, INC.

Inventor： Scott Koenig

IPC: C07K16/28 ,  C07K16/10 ,  C07K16/08

CPC classification number: C07K16/283 ,  A61K2039/505 ,  C07K16/084 ,  C07K16/085 ,  C07K16/1027 ,  C07K16/1063 ,  C07K16/2809 ,  C07K2317/31 ,  C07K2317/626 ,  C07K2317/73 ,  C07K2317/92 ,  C12N5/0638 ,  C12N2510/00 ,  C12N2710/16211 ,  C12N2710/20011 ,  C12N2740/16111 ,  C12N2760/18511

Abstract: The present invention relates to bispecific molecules that are capable of localizing an immune effector cell that expresses an activating receptor to a virally infected cell, so as to thereby facilitate the killing of the virally infected cell. In a preferred embodiment, such localization is accomplished using bispecific molecules that are immunoreactive with an activating receptor of an immune effector cell and to an antigen expressed by a cell infected with a virus wherein the antigen is detectably present on the cell infected with the virus at a level that is greater than the level at which the antigen is detected on the virus by the bispecific molecules, and to the use of such bispecific molecules in the treatment of latent viral infections.

Abstract translation: 本发明涉及能够定位表达病毒感染细胞的激活受体的免疫效应细胞的双特异性分子，从而有助于杀死病毒感染的细胞。 在优选的实施方案中，使用与免疫效应细胞的活化受体免疫反应的双特异性分子和由病毒感染的细胞表达的抗原来实现这种定位，其中抗原可检测地存在于感染病毒的细胞上 比通过双特异性分子在病毒上检测抗原的水平高的水平，以及这种双特异性分子在潜伏性病毒感染的治疗中的用途。

公开(公告)号：US20150152420A1

公开(公告)日：2015-06-04

申请号：US14550399

申请日：2014-11-21

Applicant: XIAOYONG BAO ,  YONG SUN LEE

Inventor： XIAOYONG BAO ,  YONG SUN LEE

IPC: C12N15/113 ,  A61K45/06 ,  A01K67/027 ,  A61K31/713

CPC classification number: A01K67/0271 ,  A61K31/713 ,  A61K45/06 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2760/18511 ,  C12N2310/3521

Abstract: Provided herein are methods for altering respiratory syncytial virus (RSV) replication in a cell using oligonucleotides derived from tRNAs, also referred to as tRFs (tRNA-derived RNA Fragments). The oligonucleotides may be used to decrease or increase replication of RSV. Also provided herein are methods for treating a subject having or at risk of having an RSV infection, and animal models for evaluating viral and host factors in RSV pathogenesis.

Abstract translation: 本文提供了使用衍生自tRNA（也称为tRNA衍生的RNA片段）的寡核苷酸改变细胞中呼吸道合胞病毒（RSV）复制的方法。 寡核苷酸可用于降低或增加RSV的复制。 本文还提供了治疗患有RSV感染或具有RSV感染风险的受试者的方法，以及用于评估RSV发病机理中的病毒和宿主因子的动物模型。